Completed PHASE1 INTERVENTIONAL 1-arm NCT00002587

Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors

A PHASE I STUDY OF PROLONGED LOW-DOSE TOPOTECAN INFUSION COMBINED WITH PACLITAXEL (TAXOL)

Sponsor: National Cancer Institute (NCI)

Conditions Unspecified Adult Solid Tumor, Protocol Specific

Interventions paclitaxel topotecan hydrochloride

Updated 6 times since 2017 Last updated: May 31, 2013 Started: Sep 30, 1994 Primary completion: Dec 31, 2000 Completion: Dec 31, 2000

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Unspecified Adult Solid Tumor, Protocol Specific, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 6 data snapshots since 1994. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Sep 1994

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States